

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

SURGIDYNE INC
Form 10QSB/A
May 21, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2002

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT.

Commission File Number 33-13058-C

SURG II, INC.
(Name of small business issuer in its charter)

Minnesota 58-1486040
(State or other jurisdiction of (I.R.S. Employer
incorporation of organization) Identification Number)

825 Southgate Plaza, 5001 W. 80th Street, Bloomington, MN 55437
(Address if principal executive offices)

(952) 830-1230
(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter periods that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
past 90 days. YES NO

7,447,085 shares of Common Stock, no par value, outstanding at
March 31, 2002

Transitional Small Business Disclosure Format. YES NO

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SURG II, INC.

CONTENTS	PAGE
----------	------

FINANCIAL STATEMENTS	
Balance sheets	3
Statements of operations	5
Statements of cash flows	6
Notes to financial statements	7

SURG II, INC.
BALANCE SHEETS

	March 31, 2002 (unaudited)	December 31, 2001
ASSETS		
Current Assets		
Cash	\$ 64,794	\$ 8,150

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

Accounts receivable, less allowance for doubtful accounts of \$4,200 in 2001	-	44,734
Inventories	-	124,712
Prepaid expenses	2,776	12,243
<hr/> Total current assets	67,570	189,839
<hr/> Furniture and Equipment, at cost	-	353,917
Less accumulated depreciation and amortization	-	338,003
<hr/> Total furniture and equipment	-	15,914
<hr/> Other Assets		
Patents and trademarks, net of accumulated amortization of \$19,020 in 2001	-	3,627
<hr/> Total assets	\$ 67,570	\$ 209,380

=====
See Notes to Financial Statements.

SURG II, INC.
BALANCE SHEETS (continued)

	March 31, 2002 (unaudited)	December 31, 2001
<hr/> LIABILITIES AND STOCKHOLDERS' DEFICIT		
<hr/> Current Liabilities		
Current maturities of capital lease	\$ -	\$ 5,000
Notes payable to officers and directors	-	8,474
Other notes payable	20,000	61,646
Accounts payable	38,475	119,210
Accrued expenses	30,000	56,401

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

Total current liabilities	88,475	250,731
Capital lease obligation, less current maturities	-	5,507
Stockholders' Deficit		
Series A Preferred stock, authorized 1,600,000 shares; \$400,000 liquidation preference, 1,600,000 shares Issued and outstanding	400,000	400,000
Common stock, no par value; authorized 200,000,000 shares; Issued and outstanding 7,447,085 shares	4,616,266	4,606,266
Accumulated deficit	(5,037,171)	(5,053,124)
Total stockholders' deficit	(20,905)	(46,858)
Total liabilities and stockholders' deficit \$	67,570	\$ 209,380

See Notes to Financial Statements

SURG II, INC.
STATEMENTS OF OPERATIONS (UNAUDITED)

Three Months Ended	March 31, 2002	March 31, 2001
Net sales	\$ 33,133	\$ 130,064
Cost of goods sold	31,524	93,828
Gross profit	1,609	36,236
Operating expenses		
Research and development	1,026	3,548
Sales and marketing	2,977	9,333

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

General and administrative	39,039	70,203
Total operating expenses	43,042	83,084
Operating loss	(41,433)	(46,848)
Other Income (expense)		
Net gain on sale of net assets	57,067	
Interest income	1	14
Interest expense	(210)	(1,185)
Other	528	32
Net income (loss)	\$ 15,953	\$ (47,987)
=====		
Basic and diluted net income (loss) per common share	\$ -	\$ (0.01)
=====		
Weighted average common shares outstanding-basic	7,447,085	7,447,085
=====		
Weighted average common shares outstanding-diluted	10,647,085	7,447,085
=====		

See Notes to Financial Statements

SURG II, INC.
STATEMENTS OF CASH FLOWS (UNAUDITED)

Three Months Ended	March 31, 2002	March 31, 2001
Cash Flows from Operating Activities		
Net income (loss)	\$ 15,953	\$ (47,987)
Adjustments to reconcile net income (loss) to net Cash provided by operating activities:		
Net gain on sale of net assets	(57,067)	-
Depreciation and amortization	-	24,635
Noncash compensation	10,000	-
Changes in assets and liabilities, net of effect of sale of net assets:		
Accounts receivable	6,267	(7,379)
Inventories	6,474	25,584
Prepaid expenses	9,467	(39)
Accounts payable and		

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

accrued expenses	(33,556)	19,237
<hr/>		
Net cash provided by (used in) operating activities	(42,462)	14,051
<hr/>		
Cash Flows from Investing Activities		
Net proceeds from sale of net assets	149,226	-
Cash Flows from Financing Activities		
Payments on notes payable	(50,120)	-
Payments on capital lease obligation	-	(1,109)
<hr/>		
Net cash used in financing activities	(50,120)	(1,109)
<hr/>		
Increase in cash	56,644	12,942
<hr/>		
Cash:		
Beginning	8,150	33,924
<hr/>		
Ending	\$ 64,794	\$ 46,866
<hr/>		
Supplemental Disclosures of Cash Flow Information		
Cash payments for interest	\$ 6,105	\$ 623
Supplemental Disclosures of Non-cash Investing and Financing Activities		
Common stock warrant issued for services	\$ 10,000	\$ -

See Notes to Financial Statements

SURG II, INC.

NOTES TO FINANCIAL STATEMENTS (unaudited)

Note. 1 Financial Statements

The balance sheet as of March 31, 2002 and the statements of operations and cash flows for the three month periods ended March 31, 2002 and 2001 have been prepared by the Company without audit. In the opinion of management, all adjustments (consisting solely of normal, recurring adjustments) necessary to present fairly the financial position at March 31, 2002; the results of operations and cash flows for the three month periods ended March 31, 2002 and March 31, 2001, have been made. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to such rules and regulations, although management believes the disclosures are adequate to make the information presented not misleading. The balance sheet at December

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

31, 2001 has been taken from the audited financial statements at that date. These interim financial statements should be read in conjunction with the Company's annual financial statements and related notes there to included in the Company's form 10-KSB for the year ended December 31, 2001. Results of operations for the interim periods are not necessarily indicative of future financial conditions or operating results, especially considering the sales of net assets discussed in Note 2.

Note 2. Sale of Net Operating Assets and Going Concern Considerations:

On January 22, 2002, pursuant to an agreement, the Company closed on the sale of substantially all of its net operating assets. The sale resulted in gross proceeds of \$200,000 and a gain of approximately \$4,000 after considering total transaction costs of \$104,000 including \$55,000 that were incurred and expensed in 2001. After the sale the Company has no sources of revenue as the net operating assets sold represent substantially all of its operations. The Company believes that the asset sale will enable the Company to seek a business combination or other transaction with an opportunity that will be more attractive than the Company's former wound drainage business. The Company hopes to utilize its remaining capital structure to attract a business opportunity that will maximize potential value to shareholders, see Note 3. However, there can be no assurance that a business combination or similar transaction will occur. Moreover, without a source of revenues, the Company's ability to continue as a going concern is dependent on a business combination or other transaction occurring. The Company currently has no continuing operations. The financial statements do not reflect any adjustments that might be necessary should the Company not remain as a going concern.

A summary of the asset sale is as follows:

Proceeds	\$200,000
Transaction costs	104,000
Net proceeds	\$ 96,000
Less net book value of assets sold	(92,160)
Gain	\$3,840

The actual gain recorded in the statements of operations for the three months ended March 31, 2002 is approximately \$57,000 as \$54,000 of the total transaction costs of \$104,000 were incurred and expensed in 2001. The net proceeds of approximately \$150,000 reflected in the accompanying March 31, 2002 statement of cash flows is comprised of the gross proceeds received of \$200,000 less the transaction costs incurred and expensed in 2002 of approximately \$50,000.

A summary of the net assets sold is as follows:

Accounts receivable	\$ 38,467
Inventories	118,238
Other assets	3,627
Furniture and equipment	15,914
Long-term debt	(10,506)
Accounts payable	(73,580)
Net assets sold	\$ 92,160

Because the Company sold all of its net operating assets, on a pro forma basis there would have been no sales in either period presented, assuming the transaction had been effective January 1, 2001.

Note 3. Letter of Intent with Metalclad Corporation Regarding Sale of Capital Stock

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

On March 21, 2002, the Company signed a non-binding letter of intent with Metalclad Corporation (NASDAQ: MTLCL) to sell a majority ownership interest in the Company's capital stock to Metalclad or its subsidiary for \$3,000,000 through the sale of a sufficient number of shares to provide Metalclad with 90% of the outstanding shares assuming the conversion of the Preferred shares outstanding, conversion of all warrants outstanding and any shares issued in connection with compensating investor's investment banker and executives and directors of the Company. Metalclad Corporation provides insulation and asbestos abatement services, primarily on the West Coast, to a wide range of industrial, commercial and public agency clients. The anticipated operation of the Company, as well as the board of director and officer positions, following such stock sale has not yet been determined. One officer of the Company currently owns less than one percent of the outstanding common stock of Metalclad Corporation.

The consummation of the sale of common stock to Metalclad Corporation is contingent upon the occurrence of a number of events, including completion of due diligence by Metalclad Corporation. There is no assurance that the Company will close on the sale of common stock to Metalclad Corporation. If the Company does not close on the sale of common stock to Metalclad Corporation, it intends to continue to explore strategic opportunities for raising capital for the Company.

Note 4. Income taxes

No income tax provision has been presented for the period ended March 31, 2002 due to the utilization of net operating losses.

Note 5. Net Earnings (Loss) Per Share

Basic per-share amounts are computed, generally, by dividing net income by the weighted-average number of common shares outstanding. Diluted per-share amounts assume the conversion, exercise, or issuance of all potential common stock instruments unless the effect is anti-dilutive. Because the Company incurred a loss for the three month period ended March 31, 2001, the inclusion of the common stock equivalents in the calculation of the diluted loss per share would have an anti-dilutive effect. Therefore basic and diluted loss per share are the same in the three month period ended March 31, 2001. The diluted earnings per share calculation for the three month period ended March 31, 2002, includes the 3,200,000 shares of common stock resulting from the assumed conversion of the preferred stock.

ITEM 2. Management's Discussion and Analysis or Plan of Operations

Results of Operations - 2002 compared to 2001

Overview: On January 22, 2002, pursuant to an agreement and shareholder approval, the Company closed on the sale of substantially all of its net operating assets. The sale resulted in a gain of approximately \$4,000 with gross cash proceeds of \$200,000. See Note 2 to the financial statements for further information. After the sale the Company has no sources of revenue as the net operating assets sold represented substantially all of its operations. The Company believes that the asset sale will enable the Company to seek a business combination or other transaction with an opportunity that will be more attractive than the Company's former wound drainage business. The Company hopes to utilize its remaining capital structure to attract a business opportunity that will maximize potential value to shareholders. On March 21, 2002, the Company signed a non-binding

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

letter of intent with Metalclad Corporation to sell a majority ownership interest in the Company's common stock, see Note 3 to the interim financial statements above. However, there can be no assurance that this transaction will close on terms acceptable to the Company. Moreover, without a source of revenues, the Company's ability to continue as a going concern is dependent on such a business combination or other transaction occurring.

Sales. Sales for the first three months of fiscal 2002 were \$33,133, compared to \$130,064 in fiscal 2001, a decrease of approximately 75%. This decrease was primarily related to the sale of net assets, as sales activity ceased after January 22, 2002.

Gross Profit. Gross profit expressed as a percentage of sales decreased from approximately 28% for the first three months of 2001 to approximately 5% for the same period in 2002 due primarily to less sales volume in which to spread certain fixed manufacturing costs.

Operating Expenses. Operating expenses decreased from \$83,084 for the three-month period ended March 31, 2001 to \$43,042 for the period ended March 31, 2002. The decrease was primarily the result of the sale of net assets, as operating activities ceased after January 22, 2002.

Liquidity and Capital Resources.

At March 31, 2002, the Company had a working capital deficit of \$20,905 compared to working capital deficit of \$60,892 at December 31, 2001. The slight improvement in the working capital deficit was primarily the result of the proceeds from the net asset sale as offset by payments made to retire notes payable and satisfy other operating liabilities.

The net cash used in operating activities for the three month period ended March 31, 2002 of \$42,462 was comprised of the net income of \$15,953 offset by the net gain on asset sale of \$57,067, noncash compensation of \$10,000 and the negative net change in operating assets and liabilities of \$11,348. Net cash from investing activities was comprised of the net proceeds received from the net asset sale. Net cash used in financing activities was the result of payments made to retire the note payable obligations.

As discussed in the overview above, the ability of the Company to continue as a going concern and its short-term liquidity is dependent upon obtaining additional debt and/or equity financing to fund a business combination or other transaction. The Company hopes to utilize its remaining capital structure to attract a business opportunity that will maximize potential value to shareholders. However, there can be no assurance that the possible sale of Company's common stock to Metalclad Corporation, as discussed above and in Note 3 to the interim financial statements, will actually close. Moreover, without a source of revenues, the Company's ability to continue as a going concern is dependent on a business combination or other transaction occurring. Without raising additional debt or equity, the Company may be forced to cease any further activities in the near term.

Recently Issued Accounting Pronouncements

In July 2001, FAS 141, Business Combinations, and FAS 142, Goodwill and Other Intangible Assets, were issued. These pronouncements provide that all business combinations initiated after June 30, 2001 be accounted for using the purchase method and that goodwill be reviewed for impairment rather than amortized, beginning on January 1, 2002. The adoption of these pronouncements did not have a material effect on its financial statements. Any business combination transactions in the future would be accounted for under this new guidance.

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

In September 2001, the FASB issued Statement 143, Asset Retirement Obligations. This Statement addresses financial accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs. The Statement will be effective for the Company's fiscal year ending December 2003. The Company does not believe that the adoption of this pronouncement will have a material effect on its financial statements.

In August 2001, the FASB issued Statement 144, Accounting for Impairment or Disposal of Long-Lived Assets. This Statement addresses financial accounting and reporting for the impairment or disposal of long-lived assets. The Statement will be effective for the Company's fiscal year ending December 2002. The Company does not believe that the adoption of this pronouncement will have a material effect on its financial statements.

Forward-looking statements contained in this annual report on Form 10-QSB, including without limitation in Management's Discussion and Analysis, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain important factors could cause results to differ materially from those anticipated by some statements made herein. Investors are cautioned that all forward-looking statements involve risks and uncertainties. A number of factors that could cause results to differ materially are those discussed in our Annual Report on Form 10-KSB and other recent filings with the Securities and Exchange Commission. Additional factors that could cause results to differ materially include but are not limited to, the Company's ability to consummate the sale of capital stock to Metalclad Corporation or to identify, negotiate and consummate another transaction that raises capital for the Company if the stock sale to Metalclad Corporation is not completed. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements. In addition, the Company disclaims any obligation to update forward-looking statements to reflect events or circumstances after the date hereof.

Risk Factors

The Company may not consummate the sale of common stock to Metalclad Corporation. There is no assurance that the Company will close on the sale of common stock to Metalclad Corporation or that, if consummated, it will be on as favorable terms as contemplated by the Letter of Intent. If the Company does not close with Metalclad Corporation it intends to continue to explore strategic opportunities for raising capital for the Company. However, there can be no assurance that the Company will be able to complete a transaction with another operating business. Further, even if such a transaction is completed with Metalclad Corporation or another operating business, there can be no assurances that the market price of the Company's common stock will improve.

The Company has no current operations. The Company sold all its net operating assets in January 2002. Therefore the Company has no sources of revenues and essentially no operating activities. The Company's continuing existence is dependent upon either closing on the pending transaction with Metalclad or consummating a similar transaction in the near term.

The Company's current shareholders will be diluted if we close on the sale of common stock to Metalclad Corporation. The sale of shares of the Company's common stock to Metalclad Corporation will immediately reduce the percentage ownership of our then current shareholders.

The Company's current shareholders may be diluted if the Company is successful in its efforts to convert outstanding preferred stock into common

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

stock and to have certain of its outstanding warrants exercised. The Company intends to make a proposal to its preferred shareholders to convert each share of preferred stock into two shares of common stock. In addition, the Company intends to make a proposal to some of its warrant holders to exercise their warrants such that a certain number of warrants will be cancelled in exchange for a certain number of shares of the Company's common stock, and no cash would be paid for such exercise and exchange. The issuance of the Company's common stock upon such preferred share conversions and warrant exercises may cause our shareholders to incur substantial dilution in net book value per share of common stock.

PART II. OTHER INFORMATION

ITEMS 1, 2, 3 and 5. Not Applicable.

ITEM 4. Submission of Matters to a Vote of Security Holders

(a) A special meeting of the shareholders of the Company was held on January 22, 2002.

(c) At the meeting, the shareholders approved the following items: (i) the sale of substantially all of the assets of the Company pursuant to the Asset Purchase Agreement by and between the Company and Oxboro Medical, Inc. (n/k/a Sterion Incorporated) dated October 4, 2001, as amended - 5,906,249 shares voting For, 1,500 shares voting Against and 27,250 shares Abstaining; (ii) an amendment to the Company's Articles of Incorporation to increase from the number of authorized shares to 200,000,000 -5,889,049 shares voting For, 18,200 shares voting Against and 27,750 shares Abstaining; (iii) an amendment to the Company's Articles of Incorporation to change the Company's name to Surg II, Inc. - 5,905,249 shares voting For, 1,500 shares voting Against and 28,250 shares Abstaining.

ITEM 6. Exhibits and Reports on Form 8-K

(a) Listing of Exhibits:

4.2 Secured Promissory Note to Gray, Plant, Mooty, Mooty & Bennett, P.A.

(b) Reports on Form 8-K

A Form 8-K was filed on February 6, 2002 regarding the January 22, 2002 sale of net operating assets.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SURG II, INC.
(Registrant)

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

Date: May 17, 2002

/s/ Theodore A. Johnson
By: Theodore A. Johnson
President and Principal
Accounting Officer

EXHIBIT 4.2

SECURED PROMISSORY NOTE

\$20,000

January 22, 2002

FOR VALUE RECEIVED, the undersigned Maker promises to pay to Gray, Plant, Mooty, Mooty & Bennett, P.A., at 3400 City Center, 33 South Sixth Street, Minnesota, or such other place as the holder of this Note may designate in writing to Maker, the principal sum of Twenty Thousand Dollars (\$20,000). Principal is due and payable in lawful money of the United States of America.

Principal is due and payable on demand on the earlier of a) such time as the Maker completes in one or more offerings of debt or equity which in part or in aggregate equals or exceeds Fifty Thousand Dollars, b) at any time after January 22, 2003, or c) immediately in the event Maker makes an assignment for the benefit of creditors or become insolvent, either because its liabilities exceed its assets or it is unable to pay its debts as they become due, or d) immediately, if a default occurs under the terms of any other transaction document or e) immediately if it fails to satisfy or appeal any judgment against it.

Therefore by way of example, if the Company raises \$25,000 on January 30, 2001 and \$30,000 on February 15, 2001 the Principal on this note will be due on February 15, 2001.

This Note may be fully or partially prepaid at any time during the term of this Note without penalty or premium.

Maker waives presentment, dishonor, protest, demand, diligence, notice of protest, notice of demand, notice of dishonor, notice of nonpayment, and any other notice of any kind otherwise required by law in connection with the delivery, acceptance, performance, default, enforcement or collection of this Note and expressly agrees that this Note, or any payment hereunder, may be extended or subordinated (by forbearance or otherwise) at any time, without in any way affecting the liability of Maker.

Maker agrees to pay on demand all costs of collecting or enforcing payment under this Note, including attorneys' fees and legal expenses, whether suit be brought or not, and whether through courts of original jurisdiction, courts of appellate jurisdiction, or bankruptcy courts, or through other legal proceedings.

This Note may not be amended or modified, nor shall any waiver of any provision hereof be effective, except only by an instrument in writing signed by the party against whom enforcement of any amendment, modification,

Edgar Filing: SURGIDYNE INC - Form 10QSB/A

or waiver is sought.

If this Note is signed by more than one person as Maker, the term "Maker" shall refer to each of them separately and to both or all of them jointly and all such persons shall be bound both severally and jointly with the other(s).

This Note shall be governed by and construed according to the laws of the State of Minnesota without regard to the conflict of laws and principles thereof.

MAKER:

SURGIDYNE, INC.

By /s/ Ted Johnson
Ted Johnson, Chairman and CEO